JP2023552149A5 - - Google Patents
Info
- Publication number
- JP2023552149A5 JP2023552149A5 JP2023532443A JP2023532443A JP2023552149A5 JP 2023552149 A5 JP2023552149 A5 JP 2023552149A5 JP 2023532443 A JP2023532443 A JP 2023532443A JP 2023532443 A JP2023532443 A JP 2023532443A JP 2023552149 A5 JP2023552149 A5 JP 2023552149A5
- Authority
- JP
- Japan
- Prior art keywords
- dose
- paliperidone
- composition according
- palmitate
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025172891A JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063119382P | 2020-11-30 | 2020-11-30 | |
| US63/119,382 | 2020-11-30 | ||
| PCT/EP2021/062144 WO2022111858A1 (en) | 2020-11-30 | 2021-05-07 | Dosing regimens associated with extended release paliperidone injectable formulations |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172891A Division JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023552149A JP2023552149A (ja) | 2023-12-14 |
| JP2023552149A5 true JP2023552149A5 (OSRAM) | 2024-05-17 |
| JP7792409B2 JP7792409B2 (ja) | 2025-12-25 |
Family
ID=75888042
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023532443A Active JP7792409B2 (ja) | 2020-11-30 | 2021-05-07 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
| JP2025172891A Pending JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025172891A Pending JP2026027249A (ja) | 2020-11-30 | 2025-10-14 | 持続放出パリペリドン注射可能製剤に関連する投与レジメン |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11324751B1 (OSRAM) |
| EP (2) | EP4385564A3 (OSRAM) |
| JP (2) | JP7792409B2 (OSRAM) |
| KR (1) | KR20230116837A (OSRAM) |
| CN (1) | CN116507320A (OSRAM) |
| AU (3) | AU2021387679B2 (OSRAM) |
| CA (1) | CA3203448A1 (OSRAM) |
| DK (1) | DK4025187T3 (OSRAM) |
| ES (1) | ES2974822T3 (OSRAM) |
| FI (1) | FI4025187T3 (OSRAM) |
| HR (1) | HRP20240086T1 (OSRAM) |
| HU (1) | HUE065387T2 (OSRAM) |
| IL (1) | IL303251A (OSRAM) |
| LT (1) | LT4025187T (OSRAM) |
| MA (1) | MA71365A (OSRAM) |
| MX (2) | MX2023006370A (OSRAM) |
| PL (1) | PL4025187T3 (OSRAM) |
| PT (1) | PT4025187T (OSRAM) |
| RS (1) | RS65133B1 (OSRAM) |
| SI (1) | SI4025187T1 (OSRAM) |
| SM (1) | SMT202400075T1 (OSRAM) |
| TW (2) | TWI838623B (OSRAM) |
| WO (1) | WO2022111858A1 (OSRAM) |
| ZA (1) | ZA202400851B (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| CA3203015A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| CN116528837B (zh) | 2020-11-30 | 2025-03-14 | 詹森药业有限公司 | 用于确保棕榈酸帕潘立酮制剂再悬浮的方法 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
| AU2022337993A1 (en) * | 2021-08-30 | 2024-04-11 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158952A (en) | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
| US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
| TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
| UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
| JP5249748B2 (ja) | 2005-04-25 | 2013-07-31 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造 |
| CN101932327A (zh) | 2007-12-19 | 2010-12-29 | 詹森药业有限公司 | 与长效注射用帕潘立酮酯相关的给药方案 |
| WO2011042453A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Subcutaneous paliperidone composition |
| KR20120116401A (ko) | 2009-10-30 | 2012-10-22 | 얀센 파마슈티카 엔.브이. | 장기-작용성의 주사가능한 팔리페리돈 에스테르와 관련된 투약 요법 |
| EP2529757B1 (en) | 2011-05-31 | 2014-01-08 | Laboratorios Farmaceuticos Rovi, S.A. | Paliperidone implant formulation |
| WO2016157061A1 (en) * | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
| FI3744326T3 (fi) * | 2015-04-07 | 2024-02-02 | Janssen Pharmaceutica Nv | Annosteluohjelma pitkävaikutteisten injektoitavien paliperidoniestereiden ottamatta jääneille annoksille |
| JP6668387B2 (ja) * | 2015-06-19 | 2020-03-18 | ヤンセン ファーマシューティカ エヌ．ベー． | 薬物の投与及び混合のための装置及び方法、並びにそのための適切な技法のトレーニング |
| ES3037855T3 (en) * | 2017-12-14 | 2025-10-08 | SpecGx LLC | One step milling process for preparing micronized paliperidone esters |
| SMT202400077T1 (it) | 2020-11-30 | 2024-03-13 | Janssen Pharmaceutica Nv | Regimi di dosaggio associati con formulazioni iniettabili di paliperidone a rilascio prolungato |
| MX2023006370A (es) | 2020-11-30 | 2023-08-07 | Janssen Pharmaceutica Nv | Regimenes de dosificacion asociados con formulaciones inyectables de paliperidona de liberacion prolongada. |
| CA3203015A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
| CN116528837B (zh) | 2020-11-30 | 2025-03-14 | 詹森药业有限公司 | 用于确保棕榈酸帕潘立酮制剂再悬浮的方法 |
| MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
| AU2022337993A1 (en) | 2021-08-30 | 2024-04-11 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
-
2021
- 2021-05-07 MX MX2023006370A patent/MX2023006370A/es unknown
- 2021-05-07 WO PCT/EP2021/062144 patent/WO2022111858A1/en not_active Ceased
- 2021-05-07 EP EP23219073.6A patent/EP4385564A3/en active Pending
- 2021-05-07 EP EP21724651.1A patent/EP4025187B1/en active Active
- 2021-05-07 TW TW110116513A patent/TWI838623B/zh active
- 2021-05-07 CN CN202180080436.4A patent/CN116507320A/zh active Pending
- 2021-05-07 ES ES21724651T patent/ES2974822T3/es active Active
- 2021-05-07 HU HUE21724651A patent/HUE065387T2/hu unknown
- 2021-05-07 TW TW113108928A patent/TWI897289B/zh active
- 2021-05-07 LT LTEPPCT/EP2021/062144T patent/LT4025187T/lt unknown
- 2021-05-07 FI FIEP21724651.1T patent/FI4025187T3/fi active
- 2021-05-07 PT PT217246511T patent/PT4025187T/pt unknown
- 2021-05-07 IL IL303251A patent/IL303251A/en unknown
- 2021-05-07 SM SM20240075T patent/SMT202400075T1/it unknown
- 2021-05-07 PL PL21724651.1T patent/PL4025187T3/pl unknown
- 2021-05-07 SI SI202130112T patent/SI4025187T1/sl unknown
- 2021-05-07 DK DK21724651.1T patent/DK4025187T3/da active
- 2021-05-07 US US17/314,281 patent/US11324751B1/en active Active
- 2021-05-07 HR HRP20240086TT patent/HRP20240086T1/hr unknown
- 2021-05-07 RS RS20240087A patent/RS65133B1/sr unknown
- 2021-05-07 AU AU2021387679A patent/AU2021387679B2/en active Active
- 2021-05-07 KR KR1020237021416A patent/KR20230116837A/ko not_active Ceased
- 2021-05-07 MA MA71365A patent/MA71365A/fr unknown
- 2021-05-07 CA CA3203448A patent/CA3203448A1/en active Pending
- 2021-05-07 JP JP2023532443A patent/JP7792409B2/ja active Active
-
2022
- 2022-05-06 US US17/738,422 patent/US12208100B2/en active Active
-
2023
- 2023-05-30 MX MX2024013364A patent/MX2024013364A/es unknown
-
2024
- 2024-01-25 ZA ZA2024/00851A patent/ZA202400851B/en unknown
- 2024-04-10 AU AU2024202306A patent/AU2024202306B2/en active Active
-
2025
- 2025-10-14 JP JP2025172891A patent/JP2026027249A/ja active Pending
-
2026
- 2026-03-12 AU AU2026201895A patent/AU2026201895A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023552329A5 (OSRAM) | ||
| JP3701870B2 (ja) | 末梢血管疾患治療のための９−デオキシ−２’，９−α−メタノ−３−オキサ−４，５，６−トリノール−３，７−（１’，３’−インターフェニ | |
| JP2023551009A5 (OSRAM) | ||
| JP3623962B2 (ja) | ヒドロキソコバラミンの鼻中投与用医薬組成物 | |
| FI4025187T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| JP2012533554A5 (OSRAM) | ||
| JPH05505618A (ja) | 相乗的治療用組成物及び方法 | |
| AU2014235346A1 (en) | Beraprost isomer as agent for the treatment of viral infection | |
| FI4025188T3 (fi) | Pitkävaikutteisiin injektoitaviin paliperidoniformulaatioihin liittyviä annosteluohjelmia | |
| EP0904097A2 (en) | Combinations of vasopressin and adrenergic agents for the treatment of cardiac arrest | |
| JP2014196328A (ja) | ニコチン性アセチルコリンα７受容体アゴニストの組合せ剤 | |
| JP2023535744A5 (OSRAM) | ||
| FI4025189T3 (fi) | Viivästetysti vapauttavaan injektoitavaan paliperidoniin liittyviä annostusohjelmia | |
| JPH10158169A (ja) | 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法 | |
| MX2009002311A (es) | Composiciones farmaceuticas para tratamiento de infecciones fungales. | |
| JP2023525697A (ja) | 抗ＳＡＲＳ－ＣｏＶ－２ウイルス薬であるＡｎｔｉｐｒｏｖｉｒ | |
| MY195178A (en) | Composition for Treating Joint Disease and Kit Containing Same | |
| US11497747B2 (en) | Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections | |
| Ananth et al. | Benztropine psychosis | |
| WO1996004917A1 (en) | Remedy for myotonic dystrophy | |
| JP2627914B2 (ja) | プロスタグランジン類の選択的作用増強剤 | |
| JPH05504957A (ja) | 療法―抵抗性精神分裂症治療用医薬 | |
| JPH11503721A (ja) | ベンズアミド誘導体の新規用途 | |
| EP1518554B1 (en) | Pharmaceutical composition for the treatment of hyperhomocysteinemia | |
| US11364218B2 (en) | Method of treating or preventing mood disorders, mental disorders, and/or chronic fatigue syndrome |